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The ability of invasive electrophysiologic studies to predict 
future arrhythmic events in patients with minimally symp 
tomatic Wolff-Parkinson-White syndrome is not known. To 
assess this ability, 42 patients with evidence of atrioventric- 
ular (AV) pre-excitation on the surface electrocardiogram 
underwent electrophysiologic studies and were then fol- 
lowed up as outpatients taking no medications. The patients 
were classified into three groups on the basis of prestudy 
symptoms: group I, 15 asymptomatic patients; group II, 10 
patients with infrequent symptoms but no documented 
arrhythmias; and group III, 17 patients with one docu- 
mented episode of supraventricular tachycardia or atria1 
fibrillation, or both. 
At electrophysiologic study, the number of patients with 
short anterograde accessory pathway effective refractory 
periods and rapid ventricular responses during induced 
atria1 fibrillation did not differ statistically among the three 
groups. During a mean follow-up period of 7.5 f 4.9 years, 
11 of the 42 patients had documented arrhythmias: 2 
patients from group II and 2 patients from group III had 
supraventricular tachycardia and 7 patients from group III 
had atria1 fibrillation. All nine patients from group III with 
Wolff-Parkinson-White syndrome is an uncommon disorder 
caused by congenital extranodal atrioventricular (AV) con- 
nections. The clinical manifestations of an extranodal path- 
way are variable, ranging from an abnormal electrocardio- 
gram (ECG) without symptoms to ventricular fibrillation and 
sudden death. Some episodes of sudden death in patients 
with pre-excitation are believed to result from degeneration 
of atria1 fibrillation with rapid ventricular response into 
ventricular fibrillation (l-6). The majority of patients who 
experience ventricular fibrillation have had previous epi- 
sodes of both atria1 fibrillation and paroxysmal supraventric- 
ular tachycardia, (1,2,4) but on rare occasions ventricular 
fibrillation can be the initial presenting manifestation of 
Wolff-Parkinson-White syndrome (2,3). For this reason it 
would be desirable to have a method of identifying asymp- 
tomatic patients at high risk of having atria1 fibrillation with 
a rapid ventricular response and therefore a theoretically 
increased risk of having ventricular fibrillation. 
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Some investigators (2,5,7-13) have suggested that mea- 
surement of the anterograde accessory pathway effective 
refractory period and the minimal pre-excitation RR interval 
during induced atria1 fibrillation may be a way to assess the 
risk of sudden death in these patients. Recently, Milstein et 
al. (14) reported on a series of asymptomatic patients with 
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subsequent arrhythmias had had clinical atrial fibrillation 
before study. No patient from group I had an arrhythmia 
during follow-up. There were no episodes of ventricular 
fibrillation or sudden cardiac death during follow-up in any 
of the patients. The only predischarge variables that corre- 
lated with the subsequent occurrence of arrhythmias were a 
history of documented arrhythmias before electrophysio- 
logic study (fi < 0.01) and inducible supraventricular 
tachycardia at electrophysiologic study (p < 0.05). 
From these data it is concluded that 1) patients with AV 
pre-excitation and a single episode of atrial fibrillation are 
likely to have recurrent tachyarrhythmias and should be 
treated; 2) the risk of sudden death in adults with AV 
pre-excitation but no clinical arrhythmias is probably low; 
and 3) although measurements of the accessory pathway 
effective refractory period and minimal pre-excitation cycle 
length during induced atria1 fibrillation have an excellent 
negative predictive value, the positive predictive value may 
be too low to warrant their routine use as screening tools in 
asymptomatic patients. 
(J Am Co11 Cardiol Z990;15:640-7) 
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pre-excitation who underwent electrophysiologic studies 
and were followed up without treatment. During a relatively 
short interval of 2 years, no patient had clinical arrhythmias 
although a significant proportion had had inducible arrhyth- 
mias or a rapidly conducting accessory pathway, or both. 
The purpose of this study is to report the electrophysiologic 
characteristics and subsequent long-term follow-up of a 
group of untreated patients with pre-excitation and to eval- 
uate the ability of invasive electrophysiologic studies to 
predict future arrhythmic events. 
Methods 
Study patients. Between January 1971 and May 1986, 152 
patients with manifest AV pre-excitation detected by surface 
electrocardiography underwent invasive electrophysiologic 
studies at either the University of Illinois or the West Side 
Veterans Affairs Hospital. All patients had at least one 12 
lead ECG demonstrating a short PR interval and a wide QRS 
complex associated with a delta wave during sinus rhythm. 
After electrophysiologic study, patients were discharged 
without antiarrhythmic medications if they were asympto- 
matic, symptomatic but without documented spontaneous 
arrhythmias or had had only one documented episode of 
supraventricular tachyarrhythmia or atrial fibrillation, or 
both. The 42 patients who were discharged without medical 
therapy form the basis of this prospective analysis. 
The patient characteristics were as follows: there were 37 
men and 5 women. Their ages ranged from 13 to 60 years 
(mean t 1 SD 33 rt 12.5). Organic heart disease was present 
in 10 patients: congenital heart disease in 4, hypertrophic 
cardiomyopathy in 2, coronary artery disease in 2 and mitral 
valve prolapse in 2. The left ventricular ejection fraction 
ranged from 0.41 to 0.79 (mean 0.60 ? 0.04). 
Patient groups. The patients were classified into one of 
three groups: group I consisted of 15 patients who were 
either asymptomatic (5 patients) or had extremely atypical 
symptoms not suggestive of an arrhythmia (10 patients). 
None of the patients in group I had complained of palpita- 
tion. 
Group II consisted of 10 (59%) of the 17 patients who had 
a clinical history consistent with sustained tachyarrhythmia 
hut lucked ECG confirmation. The symptoms in group II 
were palpitation (90%) dizziness (20%), syncope (lo%), 
dyspnea (40%) and chest pain (30%). The duration of symp- 
toms before electrophysiologic study ranged from 1 month to 
19 years (mean 8.0 t 7.8 years). 
Group III consisted of 17 (88%) of the 19 patients who 
had one ECG-documented episode of supraventricular 
tachycardia or cttrial fibrillation, or both. All patients had 
symptoms associated with their tachycardia: palpitation 
(lOO%), dizziness (35%), syncope (30%), dyspnea (35%), 
chest pain (24%) and cardiac arrest (12%). Both cardiac 
arrests were due to ventricular fibrillation that occurred after 
intravenous administration of digoxin and propranolol to 
patients in atria1 fibrillation. The duration of symptoms 
ranged from 2 days to 40 years (mean 9.4 t 9.1 years). 
Fifteen of the 17 patients had only a single documented 
episode of tachycardia before electrophysiologic study: par- 
oxysmal supraventricular tachycardia had occurred in 3 
patients and atrial fibrillation in 12. The other two patients 
had had one episode of both supraventricular tachycardia 
and atria1 fibrillation. In the five patients with paroxysmal 
supraventricular tachycardia, the tachycardia cycle length 
ranged from 250 to 330 ms (mean 284 + 43). In the 14 
patients with atria1 fibrillation, the mean RR interval ranged 
from 210 to 450 ms (mean 294 2 92). and the minimal 
pre-excitation RR interval during atria1 fibrillation ranged 
from 160 to 300 ms (mean 220 2 77). Twelve of the 14 
patients with atria1 fibrillation had a minimal pre-excitation 
RR interval <250 ms. There were no significant differences 
among the three groups with regard to age, ejection fraction 
or underlying heart disease. 
Electrophysiologic studies. These were performed with 
patients in the postabsorptive, nonsedated state after all 
cardioactive drugs had been discontinued for at least five 
elimination half-lives. Informed consent concerning the in- 
vestigational nature of these studies and the possibility of 
nontreatment was obtained from all patients. The method of 
data collection was approved by the institutional review 
board. 
The protocol used in this laboratory has been previously 
reported fl5,lri) and included the following: 1) recording of 
basic conduction intervals during sinus rhythm, 2) incremen- 
tal pacing at multiple atria1 sites (usually high right atrium 
and coronary sinus), 3) single atria1 extrastimulus testing 
during sinus rhythm and multiple paced cycle lengths (600 
and 500 ms), 4) incremental ventricular pacing and 5) single 
ventricular extrastimulus testing during sinus rhythm and 
multiple paced cycle lengths (600 and 500 ms). The antero- 
grade accessory pathway effective refractory period was 
defined as the longest atria1 coupling interval at which there 
was block in the accessory pathway and was measured at a 
drive cycle length of 500 ms. Sustained arrhythmias were 
defined as those lasting >30 s. Specific attempts to induce 
atrial fibrillation (done at the investigator’s discretion) were 
made in 20 of the 42 patients. Atria1 fibrillation with rapid 
ventricular response was defined as having a minimal pre- 
excitation RR interval ~250 ms. In four patients (two in 
group I and two in group II), atropine (1 mg) was given in an 
unsuccessful attempt to facilitate tachycardia induction. In 
one of the two patients from group II, isoproterenol infusion 
was used as well. Only measurements obtained before 
atropine and isoproterenol are included in this analysis. 
Atrial activation sequences from at least three atria1 sites 
during supraventricular tachycardia and ventricular pacing 
were consistent with a single accessory pathway in all but 
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Table 1. Comparison of Electrophysiologic Results in Groups I, II and III 
Group I Group II Group III 
(n = IS) (n = 10) (n = 17) p Value 
No. of patients with AP ERP <270 ms 
Mean AP ERP (ms) 
Mean AP BCL (ms) 
No. of patients with SVT induced 
Mean induced SVT CL (ms) 
No. of patients with AF induced 
Mean RR in AF (ms) 
Minimal RR in AF (ms) 
No. of patients with minimal RR 
interval <250 ms 
4 
356 t 194 
410 + 219 
3 
340 t 14 
S/8 
438 ? 106 
355 ? 120 
2 
3 
405 + 195 
437 + 208 
4 
342 + 39 
213 
390 t 113 
285 -r IOI 
0 
11 
288 + 115 
301 t 115 
12 
328 + 23 
619 
366 ? 52 
251 ” 75 
4 









*Significant for group I versus group III. AF = atrial fibrillation: AP = accessory pathway; BCL = block cycle 
length; ERP = effective refractory period; NS = not significant; SVT = supraventricular tachycardia; SVT CL = 
supraventricular tachycardia cycle length. 
one patient from group III; however, intracardiac mapping 
was incomplete in most patients. 
Follow-up. The patients were discharged without antiar- 
rhythmic medications if they were asymptomatic (15 pa- 
tients), were symptomatic but without documented arrhyth- 
mias (10 patients) or had one documented episode of 
supraventricular tachycardia or atria1 fibrillation, or both (17 
patients). These 42 patients were monitored at 3 to 12 month 
intervals either in the arrhythmia clinic or by telephone 
contact until an ECG-documented arrhythmia occurred. 
During follow-up, attempts were made to correlate the 
patients’ symptoms with ECGs during emergency room 
visits, outpatient ambulatory ECG monitoring or transtele- 
phonic recordings. Routine ambulatory ECG monitoring was 
not done in asymptomatic patients. No patient was empiri- 
cally given antiarrhythmic drugs during follow-up. Appro- 
priate antiarrhythmic therapy was begun for all patients after 
the first ECG-documented tachyarrhythmia. 
The status of patients as of October 1988 was known for 
all but three patients (one in group I and two in group III) 
who were lost to follow-up at 1,2 and 4 years, respectively. 
All three of these patients had been asymptomatic at the time 
they were last seen. The study end point was the occurrence 
of a documented arrhythmia during follow-up. Noncardiac 
death and loss of the patient to follow-up were treated as 
censored events at the time they occurred. The minimal 
follow-up time for patients arrhythmia-free during follow-up 
was 1 year. 
Statistics. Data are expressed as mean values * 1 SD. 
Statistical calculations for ordinal data involving two groups 
were performed with a nonpaired Student’s t test. Analysis 
involving three groups was done by analysis of variance and 
Scheffk multiple comparisons tests. Nominal data were 
analyzed with Fisher’s exact test and either 2 x 2 or 3 X 2 
chi-square analysis. The predictive values of various elec- 
trophysiologic variables for future arrhythmias were calcu- 
lated as follows: the positive predictive value of a given 
electrophysiologic variable equaled the number of patients 
with the given variable at electrophysiologic study who had 
arrhythmias during follow-up divided by the total number of 
patients with the given electrophysiologic variable. The 
negative predictive value of a given electrophysiologic vari- 
able equaled the number of patients without the given 
variable at electrophysiologic study and no arrhythmias 
during follow-up divided by the total number of patients 
without the given variable at electrophysiologic study. Pre- 
dictive values dealing with induced atria1 fibrillation were 
calculated with the subset of patients in which this was 
attempted. Kaplan-Meier methods were used to display 
time-related arrhythmia-free periods for the three groups. 
The probability of a true difference in outcome was deter- 
mined by the Wilcoxon test. Differences between samples 
were considered statistically significant at p < 0.05. 
Results 
Electrophysiologic studies (Table 1). All 42 patients had 
both anterograde and retrograde accessory pathway conduc- 
tion. In the 15 group I patients, the anterograde accessory 
pathway effective refractory period ranged from 200 to 1,000 
ms (mean 356 +- 194). Four patients (27%) had an accessory 
pathway effective refractory period ~270 ms. Sustained 
orthodromic AV reentrant supraventricular tachycardia 
could be induced in three (20%) of the patients in group I; the 
tachycardia cycle length ranged from 330 to 350 ms (mean 
340 2 14). Two of the three patients with inducible supraven- 
tricular tachycardia also had an accessory pathway effective 
refractory period ~270 ms. Atria1 fibrillation was induced in 
five of eight patients in whom induction was attempted. In 
two of these five patients, the minimal pre-excitation RR 
interval during atria1 fibrillation was ~250 ms. Two patients 
with induced atria1 fibrillation had inducible supraventricular 
tachycardia as well. 
In the 10 group II patients, the accessory pathway 
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effective refractory period ranged from 230 to 800 ms (mean 
405 +- 195). There were three patients (30%) with an acces- 
sory pathway effective refractory period ~270 ms. Sustained 
orthodromic supraventricular tachycardia was induced in 
four patients (40%); the tachycardia cycle length ranged 
from 3 10 to 385 ms (mean 342 t 39). One of the four patients 
with inducible supraventricular tachycardia had an acces- 
sory pathway effective refractory period ~270 ms. Atria1 
fibrillation was induced in two of three patients in whom it 
was attempted, neither of whom had a minimal pre- 
excitation RR interval ~250 ms. 
In the 17 group III patients, the accessory pathway 
effective refractory period ranged from 170 to 640 ms (mean 
288 2 115). There were 11 patients (65%) with an accessory 
pathway effective refractory period ~270 ms. Sustained 
orthodromic supraventricular tachycardia was induced in 12 
patients (71%); the tachycardia cycle length ranged from 250 
to 360 ms (mean 328 +- 23). Nine of the 12 patients with 
inducible supraventricular tachycardia also had an accessory 
pathway effective refractory period ~270 ms. Atria1 fibrilla- 
tion was induced in six of nine patients in whom induction 
was attempted; four of the six had minimal pre-excitation RR 
intervals ~250 ms. Five of the six patients with induced 
atria1 fibrillation had inducible supraventricular tachycardia 
as well. 
Supruventricular tachycardia was inducible in more pa- 
tients in group III (12 of 17) than in group I (3 of 15) (p < 
0.05). An accessory pathway effective refractory period 
~270 ms tended to occur more frequently in patients in 
group III (11 of 17) than in patients in group 1 and II (7 of 25), 
but this difference did not reach statistical significance (p = 
0.06). The mean accessory pathway effective refractory 
period, anterograde accessory pathway block cycle length, 
supraventricular tachycardia cycle length and average and 
minimal pre-excitation RR intervals during atrial fibrillation 
were not statistically different among the three groups. 
Follow-up. The minimal follow-up time for patients who 
did not have arrhythmias after electrophysiologic study was 
1 year. The follow-up time without antiarrhythmic drug 
therapy for all 42 patients ranged from 1 week to 17 years 
(mean 7.5 C 4.9 years). 
Group I putients were followed up from 1 to 17 years 
(mean 9.6 2 4.61. Of the 15 patients in group I, 4 continued 
to report atypical symptoms; however, no patient had syn- 
cope or a documented arrhythmia during follow-up. There 
were two deaths: one patient died of a ruptured abdominal 
aortic aneurysm and another of a cerebral vascular accident. 
One patient was lost to follow-up after 1 year. 
The ~follow-up time without arrhythmias for group II was 
1 week to 14 years (mean 7.6 I 5 years). Of the 10 patients 
in group II, 6 continued to describe infrequent symptoms, 
but only 2 patients (20%) had documented supraventricular 
tachycardia during follow-up at 1 week and 6 months, 
respectively, after discharge from the hospital. Both of these 
patients had had inducible supraventricular tachycardia and 
an accessory pathway effective refractory period >270 ms 
during electrophysiologic study. No patient from group II 
had atria1 or ventricular fibrillation during follow-up. 
The follow-up time without arrhythmias for group III 
rangedfrom 1 week to 13.5 years (5.7 ? 4.3 years). Of the 17 
patients in group III, 13 (77%) continued to have symptoms. 
Nine patients (53%) had a subsequently documented ar- 
rhythmic event: two patients had supraventricular tachycar- 
dia and seven patients had atria1 fibrillation with a rapid 
ventricular response. All nine of these patients had had 
spontaneous atria1 fibrillation before electrophysiologic 
study. Only six of the nine patients had had inducible 
tachycardias during electrophysiologic study: six patients 
had inducible supraventricular tachycardia and three pa- 
tients had inducible atria1 fibrillation. No patient with an 
accessory pathway effective refractory period >270 ms and 
only one patient with a minimal pre-excitation RR interval 
>240 ms during induced atria1 fibrillation developed sponta- 
neous atria1 fibrillation with a rapid ventricular response. 
Only 6 (55%) of the 11 group III patients with an acces- 
sory pathway effective refractory period ~270 ms and 1 
(25%) of the 4 patients with a minimal pre-excitation RR 
interval ~250 ms during induced atria1 fibrillation developed 
atria1 fibrillation during the follow-up period. No patient had 
ventricular fibrillation during follow-up and there were no 
deaths. Two patients were lost to follow-up after 2 and 4 
years. respectively. Of the two patients with a prior cardiac 
arrest, one had atria1 fibrillation 1.5 years later and was 
treated subsequently with disopyramide; the other is alive 
and well without therapy 12.5 years later. The patients with 
organic heart disease did not have an increased incidence of 
arrhythmias compared with those without heart disease. 
Predictors of arrhythmia occurrence. Various clinical and 
electrophysiologic indexes were compared in patients with 
and without subsequent arrhythmias (Table 2). The only 
variables that correlated with a likelihood of future arrhyth- 
mia were a history of arrhythmia before electrophysiologic 
study and inducible supraventricular tachycardia during 
electrophysiologic study. Of the 11 patients with an arrhyth- 
mic event during follow-up, 9 had had documented tachy- 
cardias before electrophysiologic testing. The other two 
patients had a clinical history of sustained palpitation con- 
sistent with undocumented arrhythmias and inducible su- 
praventricular tachycardia during electrophysiologic study. 
An accessory pathway effective refractory period ~270 ms, 
mean accessory pathway effective refractory period, mean 
anterograde accessory pathway block cycle length and in- 
duction of atria1 fibrillation did not correlate with subsequent 
arrhythmic events. The calculated negative predictive value 
of electrophysiologic study (Table 3) was high for all three 
groups; however, the positive predictive value of electro- 
physiologic study was low. 
Actuariul analysis (Fig. 1) was used to demonstrate the 
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Table 2. Comparison of Clinical and Electrophysiologic Variables With Subsequent Arrhythmic 
Events in 42 Patients 
Arrhythmia No Arrhythmia 
During Follow-Up During Follow-Up 
(n = 11) (n = 31) p Values 
Follow-up time (yr) 
AP ERP <270 ms 
Inducible SVT 
Inducible AF 
Minimal pre-excitation RR interval during AF 1250 ms 
Prior history of documented arrhythmias 
History of documented or undocumented arrhythmias 
Abbreviations as in Table 1. 
2.9 ? 3.1 9.5 ? 4.3 <0.0005 
7 II NS 
8 11 co.05 
3 10 NS 
2 4 NS 
9 8 co.01 
I1 16 co.01 
differences in natural history among the three groups. Group 
I was entirely without arrhythmias during the follow-up 
period. Patients in both groups II and III had arrhythmias 
during follow-up, but only the incidence in group III was 
statistically different from that of group I. The incidence of 
arrhythmias in group III did not reach a plateau during 
follow-up, and one to two patients a year continued to have 
arrhythmias. 
Discussion 
Previous studies. Atrioventricular pre-excitation was first 
described by Wilson (17) in 1915, but it was not until 1930 
when Wolff, Parkinson and White (18) published their de- 
scription of 11 patients with an abnormal ECG and parox- 
ysmal tachycardia that the Wolff-Parkinson-White syndrome 
was recognized as a distinct clinical entity. Since that report, 
knowledge concerning the mechanisms and treatment of 
arrhythmias associated with pre-excitation has grown tre- 
mendously, but attention has been understandably focused 
on the most symptomatic patients. The natural history of 
asymptomatic patients with an ECG showing pre-excitation, 
in particular their risk of sudden death, is still unclear. As a 
result, the appropriate management of asymptomatic pa- 
tients with pre-excitation is also unclear. 
The prevalence of ECG AV pre-excitation in the general 
population is estimated to be between 1 and 311,000 (19-23). 
The prevalence of supraventricular arrhythmias in these 
patients has been estimated to be between 4% and 80% 
(20-26). Studies showing a high prevalence of arrhythmias 
are invariably derived from hospital populations in which 
most of the patients were referred because of symptomatic 
arrhythmias. Studies (21-24) drawn from less selected pop- 
ulations demonstrate a prevalence of only 4% to 22%. In 
studies where follow-up over many years was possible, the 
incidence of subsequent tachycardias in patients asympto- 
matic at the time of the initial ECG ranges from 0% to 2% 
(21,22,24) to 45% (26). The incidence of unexplained, sudden 
or arrhythmia-related death in asymptomatic patients was 
estimated to range from 0% (22,24) to 5% (26). Again the 
higher figures come from hospital-based referral popula- 
tions. 
Thus, as a group, patients with asymptomatic pre- 
excitation appear to have an excellent prognosis and may 
not require prophylactic treatment. The prognosis of asymp- 
tomatic patients with pre-excitation, although generally ex- 
cellent, may not be uniformly so: Klein et al. (2) reported 
that in 3 (10%) of 31 patients with Wolff-Parkinson-White 
syndrome who were resuscitated from ventricular fibrilla- 
tion, the latter had been the initial symptom. All three of 
these patients were children. The knowledge that ventricular 
fibrillation can even rarely be the presenting symptom of 
Wolff-Parkinson-White syndrome has spurred interest in 
Table 3. Predictive Value of Electrophysiologic Studies for Future Arrhythmias in 42 Patients 
Positive Predictive Value (%) Negative Predictive Value (%) 
Group 1 11 Ill All 1 II III All 
History of arrhythmia* NA NA NA 53 NA NA NA 92 
Induced SVTt 0 40 18 25 100 100 83 96 
Induced SVT* 0 40 46 44 100 100 33 83 
AP ERP ~270 msf 0 0 55 36 100 100 83 93 
RR ~250 ms during induced AFS 0 0 25 17 100 100 61 93 
*Predicting occurrence of either SVT or AF; tpredicting occurrence of SVT; *predicting occurrence of AF with 
rapid ventricular response. NA = not applicable; other abbreviations as in Table 1. 
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Figure 1. Actuarial analysis of arrhythmia-free periods after elec- 
trophysiologic study for the three study groups. 
finding a means of identifying asymptomatic patients who 
are at high risk. 
Patients with Wolff-Parkinson- White syndrome who were 
resuscituted after ventricular fibrillation have usually had 
1) clinical atria1 fibrillation with rapid ventricular responses 
(1,2,27), 2) clinical supraventricular tachycardia (1,2), 
3) inducible supraventricular tachycardia or atria1 fibrillation 
with rapid ventricular responses, or both (2,3,27), 4) an 
anterograde accessory pathway effective refractory period 
~270 ms (2,3,7), and 5) multiple accessory pathways (2). 
How well these indexes can be applied to either asympto- 
matic or minimally symptomatic patients to assess future 
risk is unknown and was addressed in this study. 
Utility of electrophysiologic studies in patients with mini- 
mally symptomatic Wolff-Parkinson-White syndrome. In the 
present study, the only statistically significant difference in 
electrophysiologic variables among groups I, II and III was 
that supraventricular tachycardia was inducible in more 
patients in group III (documented supraventricular tachycar- 
dia or atria1 fibrillation) than in group I (asymptomatic or 
atypical symptoms). A number of patients in group I and 
group II (clinical history of tachycardia) had electrophysio- 
logic indexes that theoretically might indicate an increased 
risk of developing rapid atria1 fibrillation and sudden death: 
29% of the patients who had atrial fibrillation induced had a 
minimal pre-excitation RR interval <250 ms, 28% had induc- 
ible supraventricular tachycardia and 28% had an antero- 
grade accessory pathway effective refractory period ~270 
ms. Despite these “high risk” profiles, no patient in either 
group I or group II had atria1 fibrillation or sudden death 
during follow-up. In fact, no patient in group I had any 
documented arrhythmias during a mean follow-up period of 
almost 10 years. With two exceptions, the only patients in 
this series who had arrhythmias during follow-up were 
patients with a previous history of documented arrhythmias. 
The two exceptions both had a clinical history consistent 
with undocumented arrhythmias and inducible supraventric- 
ular tachycardia. 
Our results are consistent with those previously reported 
by Milstein et al. (14) in 42 asymptomatic patients with AV 
pre-excitation who underwent electrophysiologic study and 
were prospectively followed up. These investigators found 
that no patient had a subsequent arrhythmic event over a 
mean period of 2 years even though 2% had inducible 
supraventricular tachycardia, 17% had inducible atria1 fibril- 
lation with rapid ventricular responses and 21% had an 
accessory pathway effective refractory period ~270 ms. 
Milstein et al. (14) comment that atria1 fibrillation was 
difficult to induce and terminated spontaneously in all cases 
and then suggest that this may indicate a more benign 
prognosis. 
The predictive value of various electrophysiologic in- 
dexes for the three groups (Table 3) was limited: the negative 
predictive value was excellent but the positive predictive 
value was poor for all three groups. In an analysis carried out 
by Sharma et al. (28). a variety of noninvasive and invasive 
electrophysiologic tests in patients with pre-excitation and a 
wide range of symptoms were found to have good sensitivity 
but poor specificity and predictive accuracy for patients at 
risk of sudden death. These findings are consistent with our 
data as well. 
Prognosis of patients with Wolff-Parkinson-White syn- 
drome after a single episode of arrhythmia. The patients in 
group III, which consisted largely of patients with a previous 
episode of atria1 fibrillation, manifested characteristic elec- 
trophysiologic indexes, namely, inducible supraventricular 
tachycardia, a short accessory pathway effective refractory 
period and a short minimal pre-excitation RR interval in the 
patients with inducible atria1 fibrillation. However, the ar- 
rhythmia recurrence rate in group III was only 53%. It may 
be that these patients (almost all of whom had only one 
episode of tachycardia before study) have tenuous determi- 
nants for tachycardia and have arrhythmias only under 
special circumstances (altered autonomic tone or pro- 
grammed electrical stimulation, for example). Alternatively, 
some of the patients with continued symptoms might have 
been having undocumented arrhythmias. Because there was 
no plateau in the incidence of arrhythmia recurrence, it may 
be that more of these patients will eventually have a recur- 
rence. 
The absence of sudden death in this group probably 
reflects their low frequency of recurrent supraventricular 
tachycardia and atria1 fibrillation before study. In the study 
by Klein et al. (2) on ventricular fibrillation in the Wolff- 
Parkinson-White syndrome, most patients had repeated ep- 
isodes of supraventricular tachycardia and atria1 fibrillation 
before their episode of ventricular fibrillation. The patients 
in their series also had an increased incidence of multiple 
accessory pathways, whereas most of the patients in our 
study appeared to have only a single pathway. It is reason- 
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able to expect that the natural history of most minimally 
symptomatic patients with pre-excitation, short refractory 
periods and rapid conduction times more closely parallels 
that of the patients in our series than that of the patients 
reported by Klein et al. (2). We emphasize that we are not 
advocating nontreatment of patients with pre-excitation who 
have had spontaneous atria1 fibrillation with rapid ventricu- 
lar response. All such patients in our series were started on 
appropriate therapy after their first recurrence; our current 
practice is to treat all patients with atria1 fibrillation and rapid 
ventricular response after their initial presentation. The 
majority of these patients eventually have recurrent arrhyth- 
mias and the risk of sudden death over a lifetime is high 
enough to mandate treatment. 
Limitations. This study has several limitations. The small 
number of patients may result in beta type statistical errors. 
Three patients were lost to follow-up. A specific attempt to 
induce atria1 fibrillation during electrophysiologic testing 
was made on only half of the patients, which limits the 
predictive values calculated for this variable. Because clin- 
ical atria1 fibrillation did not occur in groups I and II, 
induction of atria1 fibrillation in all patients probably would 
have increased the sensitivity of that index but would have 
further decreased its specificity and predictive accuracy. 
Conclusions. Invasive electrophysiologic studies are of 
limited prognostic usefulness in patients with either asymp- 
tomic or minimally symptomatic Wolff-Parkinson-White 
syndrome. Although the findings of a long accessory path- 
way effective refractory period and noninducibility of ar- 
rhythmias can reliably assure the absence of subsequent 
arrhythmias and a low risk of sudden death, the presence of 
a short accessory pathway effective refractory period or 
inducible rapid atria1 fibrillation is not a harbinger of future 
arrhythmic events. Thus, although electrophysiologic study 
may be able to define which patients are capable of having 
serious arrhythmias, it cannot predict whether these arrhyth- 
mias will occur. Measurements of the anterograde accessory 
pathway effective refractory period or minimal pre- 
excitation RR interval during atria1 fibrillation are useful 
indexes mainly in patients with clinical arrhythmias. 
Patients without clinical arrhythmias at the time of elec- 
trophysiologic study are extremely unlikely to develop atria1 
fibrillation or to die suddenly regardless of whether the 
refractory period of the accessory pathway is long or short 
or the induced atria1 fibrillation fast or slow. In patients who 
have had spontaneous atria1 fibrillation with rapid ventricu- 
lar response, the chances of recurrence are great enough that 
all such patients should be treated after the first episode. On 
the other hand, it would be necessary to provide long-term 
treatment for many asymptomatic patients to protect the 
very few who would develop life-threatening arrhythmias. 
On the basis of this and other studies (14,28), we cannot 
recommend performing routine invasive electrophysiologic 
studies to screen asymptomatic patients. The optimal 
method of screening asymptomatic patients with pre- 
excitation to ascertain their true risk of sudden death re- 
mains to be determined. 
JACC Vol. 15, No. 3 
March 1, 1!290:640-7 
We are indebted to the late Kenneth M. Rosen, MD, under whose guidance 











Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular 
fibrillation: a possible mechanism of sudden death in patients with 
Wolff-Parkinson-White syndrome. Circulation 1971;43:520-7. 
Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher 
JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. 
N Engl J Med 1979;301:1080-5. 
Cosio TG, Benson DW, Anderson RW, et al. Onset of atria1 fibrillation 
during antidromic tachycardia: association with sudden cardiac arrest and 
ventricular fibrillation in a patient with Wolff-Parkinson-White syndrome. 
Am J Cardiol 1982;50:353-9. 
Prystowsky EN, Fananapazir L, Packer DL, Thompson KA, German 
LD. Wolff-Parkinson-White syndrome and sudden cardiac death. Cardi- 
ology 1987;74(suppl2):67-71. 
Meijler FL, van der Tweel I, Herbschleb JN, Hauer RNW, Robles de 
Medina EO. Role of atrial fibrillation and atrioventricular conduction 
(including Wolff-Parkinson-White syndrome) in sudden death. J Am Coil 
Cardiol 1985;5(suppl B): 17B-22B. 
Campbell RWF, Smith RA, Gallagher JJ, Pritchett EL, Wallace AG. 
Atria1 fibrillation in the preexcitation syndrome. Am J Cardiol 1977;40: 
514-20. 
Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibril- 
lation. Am J Cardiol 1974;34:777-82. 
Tonkin AM, Miller HC? Svenson RH, Wallace AG, Gallagher JJ. Refrac- 
tory periods of the accessory pathway in the Wolff-Parkinson-White 
syndrome. Circulation 1975;52:563-9. 
Rowland E, Curry P, Fox K, Krikler D. Relation between atrioventricular 
pathways and ventricular response during atrial fibrillation and flutter. Br 
Heart J 1981;45:83-7. 
10. Wellens HJ, Braat S, Brugada P, Gorgels AP, Bar FW. Use of procain- 
amide in patients with Wolff-Parkinson-White syndrome to disclose a 
short refractory period of the accessory pathway. Am J Cardiol 1982;50: 
1087-9. 
11. Critelli G, Grassi G, Perticone F, Coltorti F, Monda V, Condorelli M. 
Transesophageal pacing for prognostic evaluation of preexcitation syn- 







German LD, Gallagher JJ, Broughton A, Guarnieri T, Trantham JL. 
Effects of exercise and isoproterenol during atria) fibrillation in patients 
with Wolff-Parkinson-White syndrome. Am J Cardiol 1983;51:1203-6. 
Critelli G, Gallagher JJ, Perticone F, Coltorti F, Monda V, Condorelli M. 
Evaluation of noninvasive tests for identifying patients with preexcitation 
syndrome at risk of rapid ventricular response. Am Heart J 1984;108: 
905-9. 
Milstein S, Sharma AD, Klein GJ. Electrophysiologic profile of asymp- 
tomatic Wolff-Parkinson-White pattern. Am J Cardiol 1986;57:1097-100. 
Denes P, Wu D, Amat-Y-Leon F, et al. Determinants of atrioventricular 
reentrant paroxysmal tachycardia in patients with Wolff-Parkinson-White 
syndrome. Circulation 1978;58:415-25. 
Bauernfeind RA, Wyndham CRC, Swiryn SP, et al. Paroxysmal atrial 
fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1981; 
41~562-9. 
JACC Vol. 15, No. 3 








Wilson FN. A case in which the vagus influenced the form of the 
ventricular complex of the electrocardiogram. Arch Intern Med 1915;16: 
100X-29. 
Wolff I,, Parkinson J, White PD. Bundle-branch block with short P-R 
interval in healthy young people prone to paroxysmal tachycardia. Am 
Heart J 1930;5:685-704 
Hiss RG. Lamb I.E. Electrocardiographic findings in 122,043 individuals. 
Circulation 1962;25:947-61. 
Hejtmancik MR. Herrmann GR. The electrocardiographic syndrome of 
short P-R interval and broad QRS complexes. Am Heart J 1957:54: 
708-21. 
Sears GA, Manning GW. Wolff-Parkinson-White pattern in routine elec- 
trocardiography. Can Med Assoc J 1962:87:1213-7. 
Smith RF. Wolff-Parkinson-White syndrome as an aviation risk. Circula- 
tion 1964;29:67?-9. 
Guize L. Soria R. Chaouat JC. Chretien JM, Houe D, Le Heuzey JY, 
BECKMAN ET AL. 641 
tiNTREATED WOLFF-PARKINSON-WHITE SYNDROME 
Prevalence et evolution du syndrome de Wolff-Parkinson-White dans une 
population de 138.048 sujets. Ann Med Interne 1985;136:474-8. 
24. Berkman NL, Lamb LE. The Wolff-Parkinson-White electrocardiogram: 
a follow-up study of five to twenty-eight years. N Engl J Med 1%8:278: 
492-4. 
25. Flensted-Jensen E. Wolff-Parkinson-White syndrome: a long-term follow- 
up of 47 cases. Acta Med Stand 1969;186:65-74. 
26. Orinius E. Preexcitation: studies on prognosis. Acta Med Stand 1966; 
465(suppl):24-35. 
27. Morady F, Sledge C, Shen E, Sung RJ, Gonzales R. Scheinman MM. 
Electrophysiologic testing in the management of patients with the Wolff- 
Parkinson-White svndrome and atrial fibrillation. Am J Cardiol 1985:Sl: 
1623-8 
2X. Sharma AD, Yee R, Guiraudon G, Klein GJ. Sensitivity and specificity of 
invasive and noninvasive testing for risk of sudden death in Wolff- 
Parkinson-White syndrome. J Am Coil Cardiol 1987;10:373-Xl, 
